HI
BPMC

HBK Investments’s Blueprint Medicines BPMC Stock Holding History

HBK Investments’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,200,924
Closed -$410M – 249
2025
Q2 		$410M Buy
+3,200,924
New +$332M 5.35% 3
2019
Q2 		– Sell
-13,900
Closed -$1.11M – 655
2019
Q1 		$1.11M Buy
+13,900
New +$1.03M 0.01% 651
2018
Q4 		– Sell
-52,951
Closed -$4.13M – 1202
2018
Q3 		$4.13M Sell
52,951
-20,634
-28% -$1.43M 0.03% 342
2018
Q2 		$4.67M Buy
73,585
+60,429
+459% +$4.81M 0.03% 293
2018
Q1 		$1.21M Buy
13,156
+2,461
+23% +$212K 0.01% 581
2017
Q4 		$807K Sell
10,695
-5,991
-36% -$422K 0.01% 654
2017
Q3 		$1.16M Sell
16,686
-26,625
-61% -$1.42M 0.01% 592
2017
Q2 		$2.19M Buy
43,311
+8,311
+24% +$353K 0.01% 395
2017
Q1 		$1.4M Buy
+35,000
New +$1.25M 0.01% 379

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

HBK Investments's BPMC Position: Q3 2025 in Review

HBK Investments sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 3,200,924 shares — an estimated $410M sold.

HBK Investments first reported a position in BPMC in Q1 2017 and held it in 9 quarters. The position peaked at $410M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • HBK Investments reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • HBK Investments sold 3,200,924 Blueprint Medicines shares in Q3 2025, an estimated $410M.
  • HBK Investments first reported a position in Blueprint Medicines in Q1 2017 and held it in 9 quarters.
  • HBK Investments's Blueprint Medicines position peaked at $410M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on HBK Investments's 13F filing for Q3 2025, filed 14 Nov 2025.